170 related articles for article (PubMed ID: 22580817)
1. Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
Inanç M; Er O; Karaca H; Berk V; Ozkan M; Saraymen R; Elmalı F
Med Oncol; 2012 Dec; 29(5):3119-24. PubMed ID: 22580817
[TBL] [Abstract][Full Text] [Related]
2. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Akbulut H; Altuntas F; Akbulut KG; Ozturk G; Cindoruk M; Unal E; Icli F
Cytokine; 2002 Nov; 20(4):184-90. PubMed ID: 12543084
[TBL] [Abstract][Full Text] [Related]
4. Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.
Inanc M; Duran AO; Karaca H; Berk V; Bozkurt O; Ozaslan E; Ozkan M
Asian Pac J Cancer Prev; 2014; 15(1):253-6. PubMed ID: 24528035
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
[TBL] [Abstract][Full Text] [Related]
6. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
Park DJ; Yoon C; Thomas N; Ku GY; Janjigian YY; Kelsen DP; Ilson DH; Goodman KA; Tang LH; Strong VE; Coit DG; Yoon SS
Ann Surg Oncol; 2014 Apr; 21(4):1130-7. PubMed ID: 24370903
[TBL] [Abstract][Full Text] [Related]
8. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
Spencer SK; Pommier AJ; Morgan SR; Barry ST; Robertson JD; Hoff PM; Jürgensmeier JM
Br J Cancer; 2013 Nov; 109(11):2765-73. PubMed ID: 24149180
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
[TBL] [Abstract][Full Text] [Related]
10. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185
[TBL] [Abstract][Full Text] [Related]
11. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
El-Arab LR; Swellam M; El Mahdy MM
J Egypt Natl Canc Inst; 2012 Mar; 24(1):15-22. PubMed ID: 23587228
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH
BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes.
Heeschen C; Dimmeler S; Hamm CW; Boersma E; Zeiher AM; Simoons ML;
Circulation; 2003 Feb; 107(4):524-30. PubMed ID: 12566361
[TBL] [Abstract][Full Text] [Related]
14. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma.
Berglund A; Molin D; Larsson A; Einarsson R; Glimelius B
Ann Oncol; 2002 Sep; 13(9):1430-7. PubMed ID: 12196369
[TBL] [Abstract][Full Text] [Related]
15. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis.
Riccieri V; Stefanantoni K; Vasile M; Macrì V; Sciarra I; Iannace N; Alessandri C; Valesini G
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S46-52. PubMed ID: 21586218
[TBL] [Abstract][Full Text] [Related]
16. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Pilancı KN; Saglam S; Okyar A; Yucel S; Pala-Kara Z; Ordu C; Namal E; Ciftci R; Iner-Koksal U; Kaytan-Saglam E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):143-50. PubMed ID: 27270460
[TBL] [Abstract][Full Text] [Related]
17. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Shin SJ; Ahn JB; Park KS; Lee YJ; Hong YS; Kim TW; Kim HR; Rha SY; Roh JK; Kim DH; Kim C; Chung HC
Invest New Drugs; 2012 Apr; 30(2):672-80. PubMed ID: 21188464
[TBL] [Abstract][Full Text] [Related]
18. Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Ma BB; Chan SL; Ho WM; Lau W; Mo F; Hui EP; Chan C; Poon A; Dattatray RD; Wong SC; To KF; King AD; Ahuja A; Chan AT
Cancer; 2013 Dec; 119(23):4145-53. PubMed ID: 24114668
[TBL] [Abstract][Full Text] [Related]
19. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
[TBL] [Abstract][Full Text] [Related]
20. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Pineda E; Salud A; Vila-Navarro E; Safont MJ; Llorente B; Aparicio J; Vera R; Escudero P; Casado E; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Ayuso JR; Ripollés T; Bouzas R; Gironella M; García-Albéniz X; Feliu J; Maurel J
Tumour Biol; 2017 Jun; 39(6):1010428317705509. PubMed ID: 28621236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]